The ACBD6 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte cell line. This product is engineered to disrupt ACBD6 gene expression, providing a loss-of-function model to investigate the acyl-CoA binding protein??s roles in autophagy, lipid droplet dynamics, and cholesterol trafficking. The polyclonal format ensures population-level gene disruption without clonal isolation, offering a heterogeneous knockout pool suitable for studying ACBD6-dependent phenotypes in a T cell acute lymphoblastic leukemia background.
Jurkat cells are immortalized human T lymphocytes originally derived from a patient with T cell acute lymphoblastic leukemia (T-ALL). These cells harbor a PTEN-null status, leading to constitutive activation of the PI3K/AKT signaling pathway, and serve as a widely utilized model for T cell signaling, activation, and leukemia biology. The ACBD6 knockout in this PTEN-deficient background creates a unique context to examine the intersection of lipid metabolism, autophagy, and oncogenic signaling in T cell leukemia.
ACBD6 encodes a protein that binds long-chain acyl-CoA esters and functions at the nexus of fatty acid metabolism, autophagy, and intracellular cholesterol movement. Mechanistically, ACBD6 is positioned downstream of nutrient-sensing pathways regulated by upstream factors such as mTORC1, TFEB, and PPAR??, while its activity impacts downstream effectors including LC3B, p62/SQSTM1, ATG5, and the mTORC1 complex. The protein engages in direct interactions with NPC1, a cholesterol transporter implicated in Niemann-Pick disease type C, along with ATG8 family members (LC3/GABARAP), ATG7, and VPS13C. Through these molecular connections, ACBD6 couples long-chain fatty acid utilization to autophagic flux and lipid droplet homeostasis, influencing cholesterol ester formation and the dynamics of lipid droplets. Disruption of ACBD6 is predicted to alter the balance between lipid storage and autophagic degradation, with consequences for mTORC1 signaling and cellular energy metabolism.
In the Jurkat T-ALL background, ACBD6 knockout disrupts the coordination between autophagy and lipid droplet metabolism, processes critical for malignant T cell survival and proliferation. Given the PTEN deficiency and hyperactive PI3K/AKT signaling, these cells exhibit heightened reliance on metabolic adaptation, making them particularly vulnerable to perturbations in lipid and autophagic pathways. Loss of ACBD6 may impair autophagic flux and cholesterol trafficking, leading to alterations in lipid droplet accumulation and mTORC1 activity, which could affect T cell activation responses and leukemia cell viability. This model thus provides a physiologically relevant platform for dissecting ACBD6??s contributions to cancer metabolism and for probing therapeutic strategies that target lipid-mediated signaling in T-ALL.
The ACBD6 Knockout Jurkat Polyclonal Cells are designed for advanced investigations into autophagy, cholesterol transport, and lipid metabolism in leukemia contexts. Researchers can utilize this model in functional genomics studies of ACBD6, drug screening for autophagy modulators, and evaluation of therapeutic targets within lipid pathways. Representative experimental approaches include western blotting for LC3B and p62 to assess autophagic flux, BODIPY staining for lipid droplet visualization, filipin staining for cholesterol distribution, and autophagic flux assays with bafilomycin A1. Additional analyses may incorporate NPC1 immunofluorescence, flow cytometry for apoptosis (Annexin V), RT-qPCR profiling of lipid metabolism genes, LC-MS?Cbased lipidomics, and Seahorse metabolic flux analysis. These applications make the knockout cells a versatile tool for interrogating the interplay between lipid metabolism and oncogenic signaling. For further details, please contact Ascent Research.
